Harvard Pilgrim has updated our commercial prior authorization policy for the medication Opdivo to include coverage for an additional treatment indication. Following an FDA label update, Opdivo is now covered for the treatment of patients with intermediate- or poor-risk, previously untreated advanced renal cell carcinoma, in combination with ipilimumab.
Opdivo will continue to require prior authorization, which you can request by contacting CVS Health–NovoLogix via phone (844-387-1435) or fax (844-851-0882). For complete information, please refer to our updated Opdivo Medical Review Criteria
and the Opdivo Prior Authorization Request Form.